<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03854539</url>
  </required_header>
  <id_info>
    <org_study_id>Roosevelt-1</org_study_id>
    <nct_id>NCT03854539</nct_id>
  </id_info>
  <brief_title>Salivary Alpha Amylase as a Biomarker of Transdermal Vagus Nerve Stimulation</brief_title>
  <official_title>Salivary Alpha Amylase as a Biomarker of Transdermal Vagus Nerve Stimulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arkansas Tech University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arkansas Tech University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed project tests the hypothesis that salivary alpha amylase concentration is a
      reliable biomarker of the effect of transdermal vagus nerve stimulation (tVNS) in humans.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study examines the capacity of tVNS to alter the concentrations of salivary alpha
      amylase. Changes in salivary alpha amylase concentrations reflect alteration of CNS
      structures anatomically linked to the vagus, thus alertation of alpha amylase would indicate
      the efficacy of tVNS. This study is intended to study basic mechanisms and is not directed
      toward the treatment of any disease state. Particapants taking part in the study will spend
      about one hour in a single session.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 31, 2018</start_date>
  <completion_date type="Actual">June 8, 2020</completion_date>
  <primary_completion_date type="Actual">June 8, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Salivary Alpha Amylase concentration.</measure>
    <time_frame>Within single one hour session change in concentration immediately prior to and following stimulation and 5 minutes post-stimulation</time_frame>
    <description>Biomarker of autonomic arousal level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Heart Rate Variability.</measure>
    <time_frame>Within single one hour session change in heart rate variability immediately prior to and following stimulation period.</time_frame>
    <description>Change in beat to beat interval.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>No Condition Salivary Alpha Amylase</condition>
  <arm_group>
    <arm_group_label>Active Stimulation 0.5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mA intermittent transdermal stimulation of the aurical vagus stimulation 30 seconds on/30 seconds off for five cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Stimulation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>0.5mA intermittent transdermal stimulation of the aurical vagus stimulation5 Hz 30 seconds on/30 seconds off for five cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Stimulation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>0.0 mA (sham) intermittent transdermal stimulation of the aurical vagus stimulation, 0 Hz 30 seconds on/30 seconds off for five cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Stimulation 1.0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mA intermittent transdermal stimulation of the aurical vagus stimulation 30 seconds on/30 seconds off for five cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Stimulation 0.25</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.25 mA intermittent transdermal stimulation of the aurical vagus stimulation 30 seconds on/30 seconds off for five cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Transdermal Vagus Nerve Stimulation</intervention_name>
    <description>intermittent transdermal stimulation of the aurical vagus</description>
    <arm_group_label>Active Stimulation 0.25</arm_group_label>
    <arm_group_label>Active Stimulation 0.5</arm_group_label>
    <arm_group_label>Active Stimulation 1.0</arm_group_label>
    <arm_group_label>Sham Stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy individuals

        Exclusion Criteria:

          -  NA
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Arkansas Tech University</name>
      <address>
        <city>Russellville</city>
        <state>Arkansas</state>
        <zip>72801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 19, 2018</study_first_submitted>
  <study_first_submitted_qc>February 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2019</study_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Arkansas Tech University</investigator_affiliation>
    <investigator_full_name>Rodney Roosevelt</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

